In April 2022, the FDA had released and announced an industry-wide focus on more inclusive clinical studies with the goal of improving equity and diversity. FDA Commissioner, Dr. Robert Calif stated “…achieving greater diversity will be a key focus throughout the FDA to facilitate the development of better treatments and better ways to fight diseases that often disproportionately impact diverse communities.” A FDA guidance document was provided to the public, “Diversity Plans to Improve Enrollment of Participants From Underrepresented Racial and Ethnic Populations in Clinical Trials; Draft Guidance for Industry.”
CSSi has created a Diversity, Equity, and Inclusion (DEI) task force to address these concerns that focuses on increased representation and clinical trial participation in diverse communities. As an effort to further assist the clinical trial community with their DEI efforts, CSSi published the "Diversity and Inclusion Workshop: The Ultimate Guide to Ensuring Diversity and Inclusion in Clinical Trials" as well as some other resources such as “Rebuilding Trust in Clinical Trials: Diverse Patient Recruitment” and our “Clinical Trial Guide: Diversity and Inclusion”.
We have a wealth of experience successfully recruiting clinical studies with DEI initiatives and KPIs being successfully met. A case study showcasing our experience and success can be found below.
Here are some CSSi services that we offer in the DEI patient recruitment space:
If you are interested in learning more about how CSSi’s experience in DEI patient recruitment can assist your clinical study, reach out and contact us today.